tetano
Editor, Senior Moderator
J Am Chem Soc. 2013 Jan 18. [Epub ahead of print]
Co-localized delivery of adjuvant and antigen using nanolipoprotein particles (NLPs) enhances the immune response to recombinant antigens.
Fischer NO, Rasley A, Corzett M, Hwang M, Hoeprich P, Blanchette C.
Abstract
Subunit antigen-based vaccines can provide a number of important benefits over traditional vaccine candidates, such as overall safety. However, due to the inherent low immunogenicity of these antigens, methods are needed for co-localized delivery of antigen and immunostimulatory molecules, i.e. adjuvants. In this study, we devel-oped a robust vaccine delivery platform using nanolipoprotein particles (NLPs) that facilitate the co-delivery of both subunit antigens and adjuvants. Here, nickel-chelating NLPs (NiNLPs) were assembled to incorporate the amphipathic adjuvants monophosphoryl Lipid A (MPLA) and cholesterol-modified CpG oligodeoxynucleotides, capable of binding His-tagged protein antigens. Co-localization of antigen and adjuvant delivery using the NiNLP platform resulted in elevated antibody production against His-tagged influenza hemagglutinin 5 and Yersinia pestis LcrV antigens. Antibody titers in mice immunized with the adjuvanted NLP were 5 to 10 times higher than those observed with co-administration formulations and the non-adjuvanted NiNLP. Our findings demonstrate that co-localized delivery of adjuvant with antigens provides significantly greater immune stimulation in mice compared to co-administered formulations.
PMID:
23331082
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23331082
Co-localized delivery of adjuvant and antigen using nanolipoprotein particles (NLPs) enhances the immune response to recombinant antigens.
Fischer NO, Rasley A, Corzett M, Hwang M, Hoeprich P, Blanchette C.
Abstract
Subunit antigen-based vaccines can provide a number of important benefits over traditional vaccine candidates, such as overall safety. However, due to the inherent low immunogenicity of these antigens, methods are needed for co-localized delivery of antigen and immunostimulatory molecules, i.e. adjuvants. In this study, we devel-oped a robust vaccine delivery platform using nanolipoprotein particles (NLPs) that facilitate the co-delivery of both subunit antigens and adjuvants. Here, nickel-chelating NLPs (NiNLPs) were assembled to incorporate the amphipathic adjuvants monophosphoryl Lipid A (MPLA) and cholesterol-modified CpG oligodeoxynucleotides, capable of binding His-tagged protein antigens. Co-localization of antigen and adjuvant delivery using the NiNLP platform resulted in elevated antibody production against His-tagged influenza hemagglutinin 5 and Yersinia pestis LcrV antigens. Antibody titers in mice immunized with the adjuvanted NLP were 5 to 10 times higher than those observed with co-administration formulations and the non-adjuvanted NiNLP. Our findings demonstrate that co-localized delivery of adjuvant with antigens provides significantly greater immune stimulation in mice compared to co-administered formulations.
PMID:
23331082
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23331082